Publications by authors named "Bixia Tang"

Background: OH2 is an oncolytic virus derived from herpes simplex virus type 2. A phase Ia/Ib clinical trial in China was conducted in patients with unresected stage III-IV melanoma, the majority of whom had the acral type, to assess the safety and preliminary efficacy of OH2.

Methods: The trial enrolled patients with histologically confirmed unresectable stage III or advanced stage IV melanoma.

View Article and Find Full Text PDF

Elderly patients undergoing maintenance hemodialysis (MHD) face a heightened risk of cognitive frailty (CF), which significantly compromises quality of life. Early identification of at-risk individuals and timely intervention are essential. Nevertheless, current CF risk prediction models fall short in accuracy to adequately fulfill clinical requirements.

View Article and Find Full Text PDF

When classifying breeds of dogs, the accuracy of classification significantly affects breed identification and dog research. Using images to classify dog breeds can improve classification efficiency; however, it is increasingly challenging due to the diversities and similarities among dog breeds. Traditional image classification methods primarily rely on extracting simple geometric features, while current convolutional neural networks (CNNs) are capable of learning high-level semantic features.

View Article and Find Full Text PDF

Neoadjuvant PD-1 inhibitor is promising in cutaneous melanoma but remains unknown in acral melanoma (AM). This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1 toripalimab (tori) for resectable AM.

View Article and Find Full Text PDF
Article Synopsis
  • - The study assessed the safety and efficacy of the anti-PD-L1 antibody Socazolimab combined with nab-paclitaxel as a first-line treatment for advanced urothelial carcinoma (aUC), which is crucial for patients who cannot tolerate platinum-based therapies.
  • - In a multi-center phase Ib trial involving 20 patients, the combination treatment was found to be generally well-tolerated, with most adverse effects being mild (grade 1 or 2) and no severe toxicity (grade 4-5) reported.
  • - The results showed an objective response rate of 58.8% and a median progression-free survival of 8.3 months, indicating promising effectiveness for the treatment combination. *
View Article and Find Full Text PDF
Article Synopsis
  • HBM4003 is a new heavy chain-only antibody designed to work with anti-PD-1 antibody toripalimab, aiming to treat advanced solid tumors like melanoma while maintaining safety.* -
  • In a phase I trial involving 40 patients, 90% experienced some treatment-related adverse events, but no severe complications (grade 4 or 5) were reported; the treatment showed varying efficacy based on prior PD-1 treatment.* -
  • Results indicated an objective response rate of 33.3% for treatment-naïve melanoma patients, and baseline Treg/CD4+ ratio was identified as a potential predictor of treatment efficacy.*
View Article and Find Full Text PDF
Article Synopsis
  • A study focused on patients with advanced melanoma undergoing anti-PD-1 monotherapy aimed to identify and analyze hyperprogressive disease (HPD), which affects a minority subset of immunotherapy patients.
  • The research evaluated the incidence of HPD using four established definitions and found the Delta TGR > 100 definition to be most effective in predicting poorer outcomes.
  • Results showed that HPD occurred in various subtypes, with mucosal melanoma having the highest prevalence, and the presence of multiple metastatic organs significantly increased the risk of experiencing HPD.
View Article and Find Full Text PDF

Unlabelled: In medical image retrieval, accurately retrieving relevant images significantly impacts clinical decision making and diagnostics. Traditional image-retrieval systems primarily rely on single-dimensional image data, while current deep-hashing methods are capable of learning complex feature representations. However, retrieval accuracy and efficiency are hindered by diverse modalities and limited sample sizes.

View Article and Find Full Text PDF

The rapid advancement of sequencing technologies poses challenges in managing the large volume and exponential growth of sequence data efficiently and on time. To address this issue, we present GenBase (https://ngdc.cncb.

View Article and Find Full Text PDF

IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4. This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced melanoma or urothelial carcinoma (UC). Patients in phase 1a received IBI310 at 0.

View Article and Find Full Text PDF

Unlabelled: Genomic data serve as an invaluable resource for unraveling the intricacies of the higher plant systems, including the constituent elements within and among species. Through various efforts in genomic data archiving, integrative analysis and value-added curation, the National Genomics Data Center (NGDC), which is a part of the China National Center for Bioinformation (CNCB), has successfully established and currently maintains a vast amount of database resources. This dedicated initiative of the NGDC facilitates a data-rich ecosystem that greatly strengthens and supports genomic research efforts.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the long-term effectiveness and safety of the anti-PD-1 antibody toripalimab in 128 Chinese patients with advanced melanoma, focusing on acral and mucosal subtypes.
  • The treatment resulted in an overall response rate of 17.3%, with varying median survival rates based on melanoma subtype; acral melanoma had a median survival of 16.3 months, while mucosal melanoma had 10.3 months.
  • The trial demonstrated that toripalimab had a manageable safety profile and provided durable responses, although it appeared less effective as a long-term treatment for mucosal melanoma patients.
View Article and Find Full Text PDF
Article Synopsis
  • Bone metastasis (BM) in renal cell carcinoma (RCC) is linked to a poor prognosis, but there's uncertainty on how to treat patients with only bone metastases.
  • A study at Peking University Cancer Hospital analyzed data from 54 RCC patients with bone-only metastases, revealing that many faced disease progression with a median progression-free survival (PFS) of 16.2 months and overall survival (OS) of 65.2 months.
  • Results indicated that patients with fewer metastatic sites had better outcomes, and factors like the number of metastasis sites and certain RCC characteristics can help predict survival and influence treatment options.
View Article and Find Full Text PDF

Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking.

Objectives: To compare pembrolizumab versus high-dose interferon-α2b (HDI) as adjuvant therapy in pediatric patients with melanoma.

View Article and Find Full Text PDF

Biomarkers play an important role in various area such as personalized medicine, drug development, clinical care, and molecule breeding. However, existing animals' biomarker resources predominantly focus on human diseases, leaving a significant gap in non-human animal disease understanding and breeding research. To address this limitation, we present BioKA (Biomarker Knowledgebase for Animals, https://ngdc.

View Article and Find Full Text PDF

Tropical crops are vital for tropical agriculture, with resource scarcity, functional diversity and extensive market demand, providing considerable economic benefits for the world's tropical agriculture-producing countries. The rapid development of sequencing technology has promoted a milestone in tropical crop research, resulting in the generation of massive amount of data, which urgently needs an effective platform for data integration and sharing. However, the existing databases cannot fully satisfy researchers' requirements due to the relatively limited integration level and untimely update.

View Article and Find Full Text PDF

With the development of artificial intelligence (AI) technologies, biomedical imaging data play an important role in scientific research and clinical application, but the available resources are limited. Here we present Open Biomedical Imaging Archive (OBIA), a repository for archiving biomedical imaging and related clinical data. OBIA adopts five data objects (Collection, Individual, Study, Series, and Image) for data organization, and accepts the submission of biomedical images of multiple modalities, organs, and diseases.

View Article and Find Full Text PDF

Background: Acral melanoma, the most common subtype of melanoma in Asians, is often diagnosed at an advanced stage and responds poorly to current programmed cell death protein 1 (PD-1) inhibitors.

Objectives: To evaluate the safety and efficacy of TQB2450 and anlotinib in patients with advanced acral melanoma in a phase Ib study (NCT03991975).

Methods: Patients received TQB2450 (1200 mg every 3 weeks) and anlotinib (10 mg or 12 mg once daily, 2-week on/1-week off) in the dose-escalation and dose-expansion phases.

View Article and Find Full Text PDF

Background: The proliferation marker Ki67 is associated with the progression and prognosis of melanoma. However, its prognostic impact on acral melanoma (AM) remains unclear.

Methods: A total of 314 AM patients were enrolled from a cohort of 5758 patients with melanoma at Peking University Cancer Hospital between 2006 and 2018.

View Article and Find Full Text PDF

Importance: Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking.

Objective: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma.

View Article and Find Full Text PDF

Background: The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits in patients with advanced urothelial carcinoma .

View Article and Find Full Text PDF

Enhancer promoter interaction (EPI) involves most of gene transcriptional regulation in the high eukaryotes. Predicting the EPIs from given genomic loci or DNA sequences is not a trivial task. The benchmarking work so far for EPI predictors is more or less empirical and lacks quantitative model-based comparisons, posing challenges for molecular biologists to obtain reliable EPI predictions.

View Article and Find Full Text PDF
Article Synopsis
  • Aphase II trial investigated the combination of apatinib and camrelizumab for advanced acral melanoma, as current treatments are inadequate and no standard exists.
  • Out of 30 participants, the objective response rate was 24.1%, with an 82.8% disease control rate and median progression-free survival of 7.39 months.
  • The treatment was associated with manageable side effects, mainly grade 3-4 toxicities like transaminase elevations and leukocytopenia, but no treatment-related deaths occurred.
View Article and Find Full Text PDF

Background: Acral melanoma (AM) is less responsive to immunotherapy than nonacral cutaneous melanoma. Variable responses are seen during immunotherapy, including pseudoprogression, hyperprogressive disease (HPD) and heterogeneous responses. There are currently no studies on the response patterns of patients with AM treated with immunotherapy and the impact on the outcome.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session827uf6q5r4sj07lpq04bofrr74c1p1gu): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once